Chia-Chi Wang

Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection.

Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk.

Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.

Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients.

Invasive adenocarcinoma arising from a mixed hyperplastic/adenomatous polyp and synchronous transverse colon cancer.

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients.

Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters.

Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers.

Factors affecting the diagnostic accuracy of ultrasonography in assessing the severity of hepatic steatosis.

Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers.

Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo.

A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.

Hepatitis B virus infection and metabolic syndrome: fact or fiction?

Predictive factors of silent reflux in subjects with erosive esophagitis.

Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B.

Clinical, metabolic, and psychological characteristics in patients with gastroesophageal reflux disease overlap with irritable bowel syndrome.

Letter: what else can improve survival in cirrhotic patients with spontaneous bacterial peritonitis and associated septic shock?

Different risk factors between reflux symptoms and mucosal injury in gastroesophageal reflux disease.

Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma.

Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients.

Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan.

Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues.

Sulfonamide derivative targeting carbonic anhydrase IX as a nuclear imaging probe for colorectal cancer detection in vivo.

How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?

Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection.

Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg.

Clinical characteristics and psychosocial impact of different reflux time in gastroesophageal reflux disease patients.

Letter: add-on alginate therapy for reflux patients with inadequate response to a once daily proton pump inhibitor - more questions than answers.

Uncovered issues in the association between uric acid and nonalcoholic fatty liver disease.

Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.

Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.

Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma.

Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease: More questions than answer?

The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe?

Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis-offender or bystander?

Letter: programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort-more questions than answers.

The role of tea and coffee in the development of gastroesophageal reflux disease.

Systematic review: chronic viral hepatitis and metabolic derangement.

The association of vitamin D with hepatitis B virus replication: Bystander rather than offender.

Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy.

The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients: Bystander rather than offender.

Letter: outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis-more questions than answers?

Liver abscesso-colonic fistula following hepatic infarction: A rare complication of radiofrequency ablation for hepatocellular carcinoma.

Response to letter to the editor "The association of vitamin D with hepatitis B virus replication: Just the bystander?"

The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.

Response to letter to the editor "The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma".

The metabolic profiles and body composition of lean metabolic associated fatty liver disease.

One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.

Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan.

Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.

Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV Registry Program (TACR).